Future Science Group
Browse

sorry, we can't preview this file

FON-2021-1134 Suppl.docx (302.35 kB)

Supplementary Material – T cell-inflamed gene expression profile and PD-L1 expression and pembrolizumab efficacy in advanced esophageal cancer

Download (302.35 kB)
dataset
posted on 2022-07-19, 11:28 authored by Taylor & FrancisTaylor & Francis, Manish A Shah, Takashi Kojima, Daniel Hochhauser, Peter Enzinger, Judith Raimbourg, Antoine Hollebecque, Florian Lordick, Sung-Bae Kim, Masahiro Tajika, Albert Craig Lockhart, Hendrick-Tobias Arkenau, Farid El-Hajbi, Mukul Gupta, Per Pfeiffer, Pooja Bhagia, Zhu Alexander Cao, Jared Lunceford1, Shailaja Suryawanshi, Mark Ayers, Matthew J Marton, Ken Kato

 Figure S1. Patient disposition by TcellinfGEP score at data cutoff (July 30, 2018).

  

Figure S2. Patient disposition by PD-L1 CPS status at data cutoff (July 30, 2018).

  

Table S1. Baseline characteristics by TcellinfGEP score.

  

Table S2. Baseline characteristics by PD-L1 CPS status.

  

Table S3. Prevalence of TcellinfGEP and PD-L1 CPS. 

  

Table S4. Clinical utility profile for PD-L1 CPS. 

Funding

Merck Sharp and Dohme Corp.

History

Usage metrics

    Future Oncology

    Categories

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC